Passage Bio Announces Positive Interim Clinical Data from

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,University Of Pennsylvania ,Stuart Henderson ,Mark Forman ,Mike Beyer ,William Chou ,University Of Pennsylvania Gene Therapy Program ,European Commission ,Drug Administration ,Passage Bio Inc ,Healthcare Communications ,Nasdaq ,Sam Brown Inc ,Exchange Commission ,Clinical Development ,Passage Bio ,Orphan Drug ,Rare Pediatric Disease ,Gene Therapy Program ,Private Securities Litigation Reform Act ,Risk Factors ,Nasdaq Pasg ,